| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453611 | Lung Cancer | 2018 | 30 Pages |
Abstract
The presence of known somatic mutations is associated with worse DFS in resected NSCLC. The differences are both statistically significant and clinically relevant. The presence of EGFR, KRAS and TP53 mutations was also associated with adverse outcomes. Larger datasets are required to validate whether mutational status is an independent prognostic factor in early stage NSCLC.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kevin Jao, Pascale Tomasini, Suzanne Kamel-Reid, Gregorz J. Korpanty, Céline Mascaux, Shingo Sakashita, Catherine Labbé, Natasha B. Leighl, Geoffrey Liu, Ronald Feld, Penelope A. Bradbury, David M. Hwang, Melania Pintilie, Ming-Sound Tsao,